Interaction with p53 explains a pro-proliferative function for VHL in cancer
The von Hippel-Lindau (VHL) protein binds and degrades hypoxia-inducible factors (HIF) hydroxylated by prolyl-hydroxylases under normoxia. Although originally described as a tumor suppressor, there is growing evidence that VHL may paradoxically promote tumor growth. The significance of its described interactions with many other proteins remains unclear. We found that VHL interacts with p53, preventing its tetramerization, promoter binding and expression of its target genes p21, PUMA, and Bax. VHL limited the decrease in proliferation and increase in apoptosis caused by p53 activation, independent of prolyl-hydroxylation and HIF activity, and its presence in tumors caused a resistance to p53-inducing chemotherapy in vivo. We propose that VHL has both anti-tumor function, via HIF degradation, and a new pro-tumor function via p53 target (p21, PUMA, Bax) inhibition. Because p53 plays a critical role in tumor biology, is activated by many chemotherapies, and because VHL levels vary among different tumors and its function can even be lost by mutations in some tumors, our results have important clinical applications. KEY MESSAGES: VHL and p53 physically interact and VHL inhibits p53 activity by limiting the formation of p53 tetramers. VHL attenuates the expression of p53 target genes in response to p53 stimuli. The inhibition of p53 by VHL is independent of HIF and prolyl-hydroxylation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:98 |
|---|---|
| Enthalten in: |
Journal of molecular medicine (Berlin, Germany) - 98(2020), 9 vom: 28. Sept., Seite 1269-1278 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kinnaird, Adam [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Apoptosis |
|---|
| Anmerkungen: |
Date Completed 08.10.2021 Date Revised 08.10.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00109-020-01951-6 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM313009554 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM313009554 | ||
| 003 | DE-627 | ||
| 005 | 20231225145640.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00109-020-01951-6 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1043.xml |
| 035 | |a (DE-627)NLM313009554 | ||
| 035 | |a (NLM)32725274 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kinnaird, Adam |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Interaction with p53 explains a pro-proliferative function for VHL in cancer |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.10.2021 | ||
| 500 | |a Date Revised 08.10.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The von Hippel-Lindau (VHL) protein binds and degrades hypoxia-inducible factors (HIF) hydroxylated by prolyl-hydroxylases under normoxia. Although originally described as a tumor suppressor, there is growing evidence that VHL may paradoxically promote tumor growth. The significance of its described interactions with many other proteins remains unclear. We found that VHL interacts with p53, preventing its tetramerization, promoter binding and expression of its target genes p21, PUMA, and Bax. VHL limited the decrease in proliferation and increase in apoptosis caused by p53 activation, independent of prolyl-hydroxylation and HIF activity, and its presence in tumors caused a resistance to p53-inducing chemotherapy in vivo. We propose that VHL has both anti-tumor function, via HIF degradation, and a new pro-tumor function via p53 target (p21, PUMA, Bax) inhibition. Because p53 plays a critical role in tumor biology, is activated by many chemotherapies, and because VHL levels vary among different tumors and its function can even be lost by mutations in some tumors, our results have important clinical applications. KEY MESSAGES: VHL and p53 physically interact and VHL inhibits p53 activity by limiting the formation of p53 tetramers. VHL attenuates the expression of p53 target genes in response to p53 stimuli. The inhibition of p53 by VHL is independent of HIF and prolyl-hydroxylation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Apoptosis | |
| 650 | 4 | |a Proliferation | |
| 650 | 4 | |a Von Hippel-Lindau | |
| 650 | 4 | |a p53 | |
| 650 | 7 | |a Tumor Suppressor Protein p53 |2 NLM | |
| 650 | 7 | |a Von Hippel-Lindau Tumor Suppressor Protein |2 NLM | |
| 650 | 7 | |a EC 2.3.2.27 |2 NLM | |
| 700 | 1 | |a Boukouris, Aristeidis E |e verfasserin |4 aut | |
| 700 | 1 | |a Saleme, Bruno |e verfasserin |4 aut | |
| 700 | 1 | |a Dromparis, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Zervopoulos, Sotirios D |e verfasserin |4 aut | |
| 700 | 1 | |a Gurtu, Vikram |e verfasserin |4 aut | |
| 700 | 1 | |a Sutendra, Gopinath |e verfasserin |4 aut | |
| 700 | 1 | |a Michelakis, Evangelos D |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of molecular medicine (Berlin, Germany) |d 1995 |g 98(2020), 9 vom: 28. Sept., Seite 1269-1278 |w (DE-627)NLM075191725 |x 1432-1440 |7 nnns |
| 773 | 1 | 8 | |g volume:98 |g year:2020 |g number:9 |g day:28 |g month:09 |g pages:1269-1278 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00109-020-01951-6 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 98 |j 2020 |e 9 |b 28 |c 09 |h 1269-1278 | ||